TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07123103: A Dose Escalation and Expansion Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors

Sponsor: Exelixis · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 150 pts

Competing Trials Overlap

6 Active Trials

Excess Burn Exposure

$7,791,168

Rescue Site Savings

+$5,152,224

Unlock Full NCT07123103 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07123103 Rescue Dossier →